Overview

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.
Phase:
PHASE2
Details
Lead Sponsor:
Genrix (Shanghai) Biopharmaceutical Co., Ltd.